Basket trial: CTCs secondary end point Jul 20,
Post# of 153517

Jul 20, 2021:
The primary end points of the trial include the number, frequency, and severity of adverse effects, the incidence of abnormal laboratory test results, and changes in ECOG performance status from baseline to subsequently scheduled visits.
Secondary end points included PFS, ORR, clinical benefit rate, time to new metastases, changes from baseline in CTCs, and OS.
https://www.onclive.com/view/leronlimab-plus-...tatic-tnbc
But FDA does accept CTCs as an end point.

